Definium Therapeutics (DFTX) Change in Cash (2021 - 2026)

Definium Therapeutics (DFTX) has reported Change in Cash for 6 consecutive years, with $4.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Cash rose 102.45% year-over-year to $4.7 million; the TTM figure through Mar 2026 stood at $179.7 million (up 206.01% YoY), while the FY2025 annual figure was -$15.9 million, down 109.14% from the prior year.
• Change in Cash retreated to $4.7 million in Q1 2026 per DFTX's latest filing, from $237.9 million in the prior quarter.
• Across five years, Change in Cash topped out at $237.9 million in Q4 2025 and bottomed at -$190.9 million in Q1 2025.
• Historically, Change in Cash has averaged $7.6 million across 5 years, with a median of -$12.5 million in 2023.
• Annual changes were most pronounced in 2024 — Change in Cash soared 6386.57% — and 2025, when it slumped 437.63%.
• Definium Therapeutics' Change in Cash stood at -$12.4 million in 2022, then tumbled by 45.39% to -$18.0 million in 2023, then fell by 19.72% to -$21.5 million in 2024, then soared by 1204.2% to $237.9 million in 2025, then plunged by 98.03% to $4.7 million in 2026.
• Business Quant data shows DFTX's Change in Cash at $4.7 million in Q1 2026, $237.9 million in Q4 2025, and -$13.4 million in Q3 2025.